Conference abstractPublished 26 Oct 2015
State of the biosimilar industry
Pfenex Inc., USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The United States biosimilars market was established based upon The Biologics Price Competition and Innovation Act of 2009 (BPCI Act). The BPCI Act was formally passed under the Patient Protection and Affordable Care Act (ACA), and signed into law by President Barack Obama on March 23, 2010. The BPCI Act was an amendment to the Public Health Service Act (PHS Act) which created an abbreviated approval pathway known as the 351(k) pathway for biological products that are demonstrated to be highly similar (biosimilar) to a FDA approved biological product. Since March of 2010 there has been a flurry of activity in the US biosimilars market covering all aspects of the path to approval including a set of FDA guidances, 351(k) filings, and varying approaches to the “patent dance”. There has also been an emergence of biosimilar players from pure play biosimilar companies to large multinational pharmaceutical companies establishing divisions devoted to biosimilar development. This presentation will recap the evolution of the US Biosimilar market since the passage of the ACA and will explore the present and future global biosimilars opportunity.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- BylineArticles whose byline prints “Patrick Lucy”
